Multiple System Atrophy (MSA) Market is in Trends by Advancement in Therapeutics

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by poor balance and coordination due to neuronal cell loss and gliosis in multiple brain regions including the basal ganglia, cerebellum, and brainstem. The disease belongs to a family of conditions called alpha-synucleinopathies because cellular inclusions containing alpha-synuclein deposits are characteristic findings in patients with MSA. Currently, there is no cure for MSA and treatment options are limited to managing symptoms.

The Multiple System Atrophy (MSA) Market is estimated to be valued at USD 148.1 Mn in 2024 and is expected to reach USD 202.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.


Key Takeaways

Key players operating in the Multiple System Atrophy (MSA) are Chelsea Therapeutics International, Ltd.,Biohaven Pharmaceuticals, Inc.,Sumitomo Dainippon Pharma Co., Ltd.,AstraZeneca plc,Theravance Biopharma, Inc.

The increasing prevalence of MSA and lack of approved treatment options present lucrative growth opportunities for players in the Multiple System Atrophy (MSA) Market. Various drug developers are conducting clinical trials to evaluate efficacy of drugs such as Olesoxime and Tirasemtiv in MSA patients.

The growing geriatric population worldwide susceptible to neurodegenerative diseases is a major factor driving the demand for diagnosis and treatment of MSA. With no approved cure available, managing symptoms such as poor coordination and balance through physical and occupational therapy plays a pivotal role. However, high cost of therapies limits market growth to some extent.

Globally, North America dominated the MSA market owing to rising incidence, high healthcare expenditure, and presence of major players. However, emerging countries of Asia Pacific offer lucrative opportunities for market expansion due to growing healthcare infrastructure and increasing awareness.


Market key trends

One of the key trends in the MSA market is advancement in therapeutic development. Several drugs are in pipeline targeting pathological pathways and clinical manifestations of MSA. For instance, H.Lundbeck A/S is investigating Olesoxime, a neuroprotective agent that may stabilize mitochondrial function. It has received orphan drug designation from the FDA and EMA for MSA treatment. Theravance Biopharma is researching Tirasemtiv, a fast skeletal muscle troponin activator to improve mobility in MSA patients with limited ambulation. Positive results from ongoing trials can help fulfil the unmet need and drive the market growth over the forecast period.

Porter's Analysis

Threat of new entrants: High costs for R&D and clinical trials create barriers for new companies to enter the MSA market.

Bargaining power of buyers: A large number of patients suffering from MSA means buyers have moderate bargaining power to negotiate on price with existing companies.

Bargaining power of suppliers: Established distribution channels for drugs and services provide suppliers with some bargaining power over companies in the MSA market.

Threat of new substitutes: Currently there is no cure for MSA so substitute treatments only manage symptoms with limited effectiveness.

Competitive rivalry: A few major companies operating in the niche MSA market and focus on developing new treatments results in high competition.

Geographical Regions

North America currently holds the largest share of the global MSA market in terms of value owing to developed healthcare infrastructure and growing patient awareness. The US accounts for the bulk of the North American market.

Asia Pacific is poised to be the fastest growing region for the MSA market during the forecast period due to rising geriatric population, increasing healthcare spending, and growing focus of key players on expanding in China, India and other developing Asian countries.

Get This Report in Japanese Language: 多系統萎縮症市場

Get This Report in Korean Language: 다중 시스템 위축 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)